🏢 What kind of company is TIVIC Health?

TIVC (TIVIC Health) is a healthcare company founded in 2016 in the United States, headquartered in California. Jennifer Ernst serves as CEO. In its early days, the company was a single-product business that developed and sold ClearUP, a non-invasive neurostimulation medical device for sinus pain relief.

Entering 2025, the company halted commercial sales of ClearUP and paused its non-invasive vagus nerve stimulation (VNS) program, then strategically shifted to focus resources on developing biopharmaceuticals for oncology supportive care and acute radiation syndrome (ARS) response. Securing worldwide exclusive licensing rights to the TLR5 agonist entolimod from Statera Biopharma marked the key inflection point.

💰 How does it make money?

With the discontinuation of ClearUP commercial operations, TIVC has effectively lost its own product revenue, and its revenue structure has been reorganized so that future earnings depend on clinical progress and securing contracts or stockpiling demand from BARDA and other government agencies. In the short term, cost efficiency and cash runway are more important indicators than revenue.

📐 Market Cap and Company Size

Market capitalization stands at $4.0M, roughly About 0% of Samsung Electronics' market cap. Employee count is 52 people.

TIVC is a micro-cap stock with a very small market cap. Given its clinical-stage biotech nature, it has virtually no internal operating cash flow, so repeated new share issuances to raise capital are likely, posing significant dilution risk for existing shareholders. Trading volume and liquidity are also limited, making short-term volatility quite high.

📈 TIVIC Health Outlook and Stock Price Trends

Lead candidate entolimod is a TLR5 agonist class asset, with potential expansion beyond acute radiation syndrome treatment to indications including immunosenescence, lymphocyte depletion, acute neutropenia, and vaccine adjuvants. Derivative candidate Entolasta targets chronic radiation syndrome and chronic neutropenia, among others.

The company is reported to have conducted roughly 200-fold production scale-up using 50-liter fermentation with contract development and manufacturing organization (CDMO) partner Velocity Bioworks. The core of the business strategy is securing BARDA funding and signing stockpile contracts with the U.S. and allied governments. Since a single government contract can materially change the company's valuation, investors should track government announcements alongside clinical and regulatory events.

⚔️ Key Competitive Strengths and Risks

The business model pivot targets a larger market, but the stock is a high-difficulty name exposed simultaneously to clinical, funding, and government contract variables.

Competitors and Related Stocks (Beneficiaries)

Comparable clinical-stage small biotechs and government medical countermeasures (MCM) names with ARS and biodefense assets include SIGA (SIGA Technologies) and EBS (Emergent BioSolutions), which hold ARS and biodefense assets. They share a similar business model to TIVC's intended direction in that government stockpiling and contract revenue make up a large share of sales. In the non-invasive neurostimulation space, ELEC (Electrocore) has been cited as a historical peer, but with TIVC having effectively exited that area, the comparison has lost relevance.

✅ Investor Checkpoints

TIVC is a clinical-stage micro-cap stock in the middle of a business model transition. Investors should clearly understand that this is closer to betting on clinical and government contract events than typical investing.

Clinical-stage micro-cap biotechs carry structural risk in that stock prices can decline sharply over short periods from a single clinical failure, funding shortage, or collapse of a government contract. Low trading volume can also cause large differences in execution prices depending on timing.

TIVC presents an interesting attempt to pivot from a medical device company to a biopharmaceutical developer targeting the government market, but it remains a high-difficulty stock exposed simultaneously to three major variables: clinical outcomes, government contracts, and funding. The name is suitable only as a very small portion of a diversified portfolio, or for investors experienced in trading clinical and government events.

Check TIVIC Health's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.